BioSpace News Archive

Cricket Health announced a new value-based kidney care offering specifically designed for Medicare Advantage plans.

The largest single contribution to City of Hope Orange County will establish Lennar Foundation Cancer Center to accelerate the vision of eradicating cancer and creating healthier communities

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.

Approval based on CheckMate -9ER trial, in which CABOMETYX in combination with OPDIVO doubled progression-free survival and objective response rate while significantly improving overall survival versus sunitinib

Gilead Sciences, Inc. released the following statement on the death of John C. Martin, PhD, who served as the company’s chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019.

- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive top-line preliminary results from the company’s Phase 3 FOCUS trial of HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system)

HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced the publication of in vitro pharmacology data in the journal Molecular Genetics and Metabolism , demonstrating that the oral small molecule HST5040 may be effective in treating Methylmalonic Acidemia

Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the successful completion of a $116 million Series B financing.

- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, and other surgical indications, announces that Board Chairman James Sapirstein has issued a Letter to Shareholders providing a business update

Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the vision-based patient monitoring and management platform delivered as software as a service.